ABUS
Price
$4.09Alerts
Change
+$0.06 (+1.49%)
Updated
Nov 13 closing price
Capitalization
724.08M
110 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$3.37Alerts
Change
-$0.08 (-2.32%)
Updated
Nov 13 closing price
Capitalization
252.67M
108 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs BCYC

ABUS vs BCYC Comparison Chart in %
View a ticker or compare two or three
VS
ABUS vs. BCYC commentary
Nov 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Buy and BCYC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABUS with price predictions
Nov 13, 2026

ABUS sees its Stochastic Oscillator recovers from oversold territory

On November 12, 2026, the Stochastic Oscillator for ABUS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 49 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Oscillator exited the oversold zone, 19 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on November 12, 2026. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.

Following a +5.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 62 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.

The 50-day moving average for ABUS moved below the 200-day moving average on November 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

The Aroon Indicator for ABUS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.799) is normal, around the industry mean (3.498). P/E Ratio (4.627) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BCYC with price predictions
Nov 13, 2026

Aroon Indicator for BCYC shows an upward move is likely

BCYC's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator showed a similar pattern. In 121 of the 137 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 185 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

BCYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for BCYC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

BCYC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (3.498). P/E Ratio (-1.322) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ABUS vs BCYC: Fundamental Ratings
ABUS
BCYC
OUTLOOK RATING
1..100
2014
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1597
PRICE GROWTH RATING
1..100
6973
P/E GROWTH RATING
1..100
5928
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (36) in the null industry is somewhat better than the same rating for ABUS (77) in the Biotechnology industry. This means that BCYC’s stock grew somewhat faster than ABUS’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as ABUS (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for BCYC (97) in the null industry. This means that ABUS’s stock grew significantly faster than BCYC’s over the last 12 months.

ABUS's Price Growth Rating (69) in the Biotechnology industry is in the same range as BCYC (73) in the null industry. This means that ABUS’s stock grew similarly to BCYC’s over the last 12 months.

BCYC's P/E Growth Rating (28) in the null industry is in the same range as ABUS (59) in the Biotechnology industry. This means that BCYC’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSBCYC
RSI
ODDS (%)
Bullish Trend 1 day ago
70%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
76%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 14, 2026
Stock price -- (ABUS: $4.09 vs. BCYC: $3.37)
Brand notoriety: ABUS and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 68% vs. BCYC: 127%
Market capitalization -- ABUS: $724.08M vs. BCYC: $252.67M
ABUS [@Biotechnology] is valued at $724.08M. BCYC’s [@Biotechnology] market capitalization is $252.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 1 FA rating(s) are green while BCYC’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, BCYC is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while BCYC’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 4 bearish.
  • BCYC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than BCYC.

Price Growth

ABUS (@Biotechnology) experienced а +11.90% price change this week, while BCYC (@Biotechnology) price change was -6.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.

Reported Earning Dates

ABUS is expected to report earnings on Mar 04, 2027.

BCYC is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (-3.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FNDA36.210.04
+0.11%
Schwab Fundamental U.S. Small Company ETF (FNDA)
MSFD9.72-0.02
-0.21%
Direxion Daily MSFT Bear 1X ETF (MSFD)
OCTP33.34-0.10
-0.29%
PGIM S&P 500 Buffer 12 ETF - October (OCTP)
ITWO42.59-0.14
-0.33%
ProShares Russell 2000 High Income ETF (ITWO)
TDVI30.58-0.32
-1.04%
FT Vest Technology Dividend Target Income ETF (TDVI)